Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

曲妥珠单抗的毒理学：对心脏毒性机制的一种认识

卷 19, 期 5, 2019

页: [400 - 407] 页: 8

弟呕挨: 10.2174/1568009618666171129222159

价格: $65

conference banner
摘要

曲妥珠单抗是一种人源化单克隆抗体，被批准用于治疗乳腺癌和胃癌。虽然它作为一种生物治疗药物具有前景，但其心脏毒性仍然是一个主要问题。遗传毒性抗癌蒽环类抗生素如阿霉素和表柔比星也因其心脏毒性作用而闻名。然而，建议使用曲妥珠单抗和蒽环类抗生素通过不同途径介导心脏毒性。现有证据表明，曲妥珠单抗可加剧蒽环类抗生素的心脏毒性作用，因此，先前接触蒽环类抗生素被认为是曲妥珠单抗诱发心脏毒性的危险因素之一。尽管通常认为曲妥珠单抗诱导的心脏毒性作用是可逆的，但各种临床前研究已经揭示其对心肌细胞的凋亡作用。因此，其心脏毒性作用的可逆性问题仍有待完全解决。本文讨论了为曲妥珠单抗的心脏毒性作用提出的各种机制以及可能导致心脏毒性的潜在危险因素。还讨论了最近批准的抗HER2单克隆抗体，包括帕妥珠单抗和ado-trastuzumab（T-DM1）。

关键词: 曲妥珠单抗，Pertuzumab，Ado-trastuzumab，心脏毒性，乳腺癌，胃癌，危险因素。

« Previous Next »
图形摘要

[1]
Vugmeyster, Y.; Xu, X.; Theil, F.P.; Khawli, L.A.; Leach, M.W. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J. Biol. Chem., 2012, 3, 73-92.
[2]
Scott, A.M.; Wolchok, J.D.; Old, L.J. Antibody therapy of cancer. Nat. Rev. Cancer, 2012, 12, 278-287.
[3]
Chan, A.C.; Carter, P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol., 2010, 10, 301-316.
[4]
Carter, P.; Presta, L.; Gorman, C.M.; Ridgway, J.B.; Henner, D.; Wong, W.L.; Rowland, A.M.; Kotts, C.; Carver, M.E.; Shepard, H.M. Humanization of an anti-p185her2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 1992, 89, 4285-4289.
[5]
Graus-Porta, D.; Beerli, R.R.; Daly, J.M.; Hynes, N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J., 1997, 16, 1647-1655.
[6]
Citri, A.; Skaria, K.B.; Yarden, Y. The deaf and the dumb: The biology of ErbB-2 and ErbB-3. Exp. Cell Res., 2003, 284, 54-65.
[7]
Wieduwilt, M.J.; Moasser, M.M. The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell. Mol. Life Sci., 2008, 65, 1566-1584.
[8]
Pinkas-Kramarski, R.; Soussan, L.; Waterman, H.; Levkowitz, G.; Alroy, I.; Klapper, L.; Lavi, S.; Seger, R.; Ratzkin, B.J.; Sela, M.; Yarden, Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J., 1996, 15, 2452-2467.
[9]
Pohlmann, P.R.; Mayer, I.A.; Mernaugh, R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res., 2009, 15, 7479-7491.
[10]
Baselga, J. Clinical trials of herceptin (Trastuzumab). Eur. J. Cancer, 2001, 37(Suppl. 1), S18-S24.
[11]
Herceptin, full prescribing information, revised April, 2017, https://www.gene.com/download/pdf/herceptin_prescribing.pdf (Accessed Sep 19, 2017).
[12]
Herceptin, http://www.herceptin.com/ (Accessed Sep 19, 2017).
[13]
Molina, M.A.; Codony-Servat, J.; Albanell, J.; Rojo, F.; Arribas, J.; Baselga, J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res., 2001, 61, 4744-4749.
[14]
Onitilo, A.A.; Engel, J.M.; Stankowski, R.V. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: Prevalence, patient characteristics, and risk factors. Ther. Adv. Drug Saf., 2014, 5, 54-66.
[15]
Vermeulen, Z.; Segers, V.F.; De Keulenaer, G.W. ErbB2 signaling at the crossing between heart failure and cancer. Basic Res. Cardiol., 2016, 111, 60.
[16]
De Keulenaer, G.W.; Doggen, K.; Lemmens, K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ. Res., 2010, 106, 35-46.
[17]
Zeglinski, M.; Ludke, A.; Jassal, D.S.; Singal, P.K. Trastuzumab-induced cardiac dysfunction: A ‘dual-hit’. Exp. Clin. Cardiol., 2011, 16, 70-74.
[18]
Ewer, M.S.; Vooletich, M.T.; Durand, J.B.; Woods, M.L.; Davis, J.R.; Valero, V.; Lenihan, D.J. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol., 2005, 23, 7820-7826.
[19]
Telli, M.L.; Hunt, S.; Carlson, R.W.; Guardino, A.E. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J. Clin. Oncol., 2007, 25, 3525-3533.
[20]
ElZarrad, M.K.; Mukhopadhyay, P.; Mohan, N.; Hao, E.; Dokmanovic, M.; Hirsch, D.S.; Shen, Y.; Pacher, P.; Wu, W.J. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One, 2013, 8, e79543.
[21]
Barth, A.S.; Zhang, Y.; Li, T.; Smith, R.R.; Chimenti, I.; Terrovitis, I.; Davis, D.R.; Kizana, E.; Ho, A.S.; O’Rourke, B.; Wolff, A.C.; Gerstenblith, G.; Marbán, E. Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab. Stem Cells Transl. Med., 2012, 1, 289-297.
[22]
Mohan, N.; Shen, Y.; Endo, Y.; ElZarrad, M.; Wu, W.J. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol. Cancer Ther., 2016, 15, 1321-1331.
[23]
Rodríguez, C.E.; Reidel, S.I.; Bal de Kier Joffé, E.D.; Jasnis, M.A.; Fiszman, G.L. Autophagy protects from trastuzumab-induced cytotoxicity in HER2 overexpressing breast tumor spheroids. PLoS One, 2015, 10, e0137920.
[24]
Thomas, R.L.; Roberts, D.J.; Kubli, D.A.; Lee, Y.; Quinsay, M.N.; Owens, J.B.; Fischer, K.M.; Sussman, M.A.; Miyamoto, S.; Gustafsson, A.B. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev., 2013, 27, 1365-1377.
[25]
Dirks-Naylor, A.J. The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci., 2013, 93(24), 913-916.
[26]
Lu, L.; Wu, W.; Yan, J.; Li, X.; Yu, H.; Yu, X. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int. J. Cardiol., 2009, 134, 82-90.
[27]
RxList: http://www.rxlist.com/perjeta-drug.htm (accessed Jan 31, 2017).
[28]
Perjeta, full prescribing information, revised May, 2017, https://www.gene.com/download/pdf/perjeta_prescribing.pdf (accessed Sep 19, 2017).
[29]
Kondapalli, L. Cardiotoxicity: an unexpected consequence of HER2-targeted therapies. American College of Cardiology, Jun 07, 2016, http://www.acc.org/latest-in-cardiology/articles/2016/ 06/06/ 09/32/cardiotoxicity?w_nav=TI (accessed Sep 19, 2017).
[30]
Kadcyla, full prescribing information, revised July, 2016, https://www.gene.com/download/pdf/kadcyla_prescribing.pdf (accessed Sep 19, 2017).
[31]
Diessner, J.; Bruttel, V.; Stein, R.G.; Horn, E.; Häusler, S.F.; Dietl, J.; Hönig, A.; Wischhusen, J. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis., 2014, 5, e1149.
[32]
Sendur, M.A.; Aksoy, S.; Altundag, K. Cardiotoxicity of novel HER2-targeted therapies. Curr. Med. Res. Opin., 2013, 29, 1015-1024.
[33]
Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.Y.; Diéras, V.; Guardino, E.; Fang, L.; Lu, M.W.; Olsen, S.; Blackwell, K. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med., 2012, 367, 1783-1791.
[34]
Sheikh, M.S. RNA-binding Protein, GADD45-alpha, p27Kip1, p53 and genotoxic stress response in relation to chemoresistance in cancer. Mol. Cell. Pharmacol., 2015, 7, 41-45.
[35]
Chu, E.; Sartorelli, A.C. Cancer chemotherapy In: Basic & Clinical Pharmacology; Katzung B.G.; Trevor A.J., Ed.; McGraw-Hill: New York; 2015, 13th Ed., pp. 934-935.
[36]
Cookson, M.S.; Chang, S.S.; Lihou, C.; Li, T.; Harper, S.Q.; Lang, Z.; Tutrone, R.F. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther. Adv. Urol., 2014, 6, 181-191.
[37]
Cottin, Y.; Touzery, C.; Dalloz, F.; Coudert, B.; Toubeau, M.; Riedinger, A.; Louis, P.; Wolf, J.E.; Brunotte, F. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin. Cardiol., 1998, 21, 665-670.
[38]
Jain, K.K.; Casper, E.S.; Geller, N.L.; Hakes, T.B.; Kaufiiiann, R.J.; Currie, V.; Schwartz, W.; Cassidy, C.; Petroni, G.R.; Young, C.W. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J. Clin. Oncol., 1985, 3, 818-826.
[39]
Gammella, E.; Maccarinelli, F.; Buratti, P.; Recalcati, S.; Cairo, G. The role of iron in anthracycline cardiotoxicity. Front. Pharmacol., 2014, 5, 25.
[40]
Chabner, B.A.; Bertino, J.; Cleary, J.; Ortiz, T.; Lane, A.; Supko, J.G.; Ryan, D. Cytotoxic Agents. In: Brunton, L.L.; Chabner, B.A.; Knollmann, B.C. eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e New York, NY: McGraw- Hill;. http://accessmedicine.mhmedical.com/content.aspx?bookid=1613§ionid=102164019 (Accessed Sep 19, 2017).
[41]
Volkova, M.; Russell, R., III Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Curr. Cardiol. Rev., 2011, 7, 214-220.
[42]
Ewer, M.S.; Ewer, S.M. The anthracycline-trastuzumab interaction: a lesson in not jumping to confusion. Trends Pharmacol. Sci., 2015, 36, 321-322.
[43]
Zhao, L.; Zhang, B. Doxorubicin induces cardiotoxicity through upregulation of death receptorsmediated apoptosis in cardiomyocytes. Sci. Rep., 2017, 7, 44735.
[44]
Chatterjee, K.; Zhang, J.; Honbo, N.; Karliner, J.S. Doxorubicin cardiomyopathy. Cardiology, 2010, 115, 155-162.
[45]
Farolfi, A.; Melegari, E.; Aquilina, M.; Scarpi, E.; Ibrahim, T.; Maltoni, R.; Sarti, S.; Cecconetto, L.; Pietri, E.; Ferrario, C.; Fedeli, A.; Faedi, M.; Nanni, O.; Frassineti, G.L.; Amadori, D.; Rocca, A. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart, 2013, 99, 634-639.
[46]
Cochet, A.; Quilichini, G.; Dygai-Cochet, I.; Touzery, C.; Toubeau, M.; Berriolo-Riedinger, A.; Coudert, B.; Cottin, Y.; Fumoleau, P.; Brunotte, F. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res. Treat., 2011, 130, 845-854.
[47]
Russo, G.; Cioffi, G.; Di Lenarda, A.; Tuccia, F.; Bovelli, D.; Di Tano, G.; Alunni, G.; Gori, S.; Faggiano, P.; Tarantini, L. Role of renal function on development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern. Emerg. Med., 2012, 7, 439-446.
[48]
Lemieux, J.; Diorio, C.; Côté, M.A.; Provencher, L.; Barabé, F.; Jacob, S.; St-Pierre, C.; Demers, E.; Tremblay-Lemay, R.; Nadeau-Larochelle, C.; Michaud, A.; Laflamme, C. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res., 2013, 33, 569-576.
[49]
Serrano, C.; Cortés, J.; De Mattos-Arruda, L.; Bellet, M.; Gómez, P.; Saura, C.; Pérez, J.; Vidal, M.; Muñoz-Couselo, E.; Carreras, M.J.; Sánchez-Ollé, G.; Tabernero, J.; Baselga, J.; DiCosimo, S. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann. Oncol., 2012, 23, 897-902.
[50]
Han, W.; Kang, D.; Lee, J.E.; Park, I.A.; Choi, J.Y.; Lee, K.M.; Bae, J.Y.; Kim, S.; Shin, E.S.; Lee, J.E.; Shin, H.J.; Kim, S.W.; Kim, S.W.; Noh, D.Y. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin. Cancer Res., 2005, 11, 4775-4778.
[51]
Lemmon, M.A.; Schlessinger, J.; Ferguson, K.M. The EGFR family: Not so prototypical receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol., 2014, 6, a020768.
[52]
Fleishman, S.J.; Schlessinger, J.; Ben-Tal, N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc. Natl. Acad. Sci. USA, 2002, 99, 15937-15940.
[53]
Jorissen, R.N.; Walker, F.; Pouliot, N.; Garrett, T.P.; Ward, C.W.; Burgess, A.W. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res., 2003, 284, 31-53.
[54]
Zhang, X.; Gureasko, J.; Shen, K.; Cole, P.A.; Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell, 2006, 125, 1137-1149.
[55]
Beauclair, S.; Formento, P.; Fischel, J.L.; Lescaut, W.; Largillier, R.; Chamorey, E.; Hofman, P.; Ferrero, J.M.; Pagès, G.; Milano, G. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann. Oncol., 2007, 18, 1335-1341.
[56]
Mailliez, A.; Révillion, F.; Ploquin, A.; Servent, V.; Bonneterre, J. Trastuzumab cardiac toxicity and HER2 polymorphism: A casecontrol study. Cancer Res, 2010, 70, Abst P3-14-11.
[57]
Stanton, S.E.; Ward, M.M.; Christos, P.; Sanford, R.; Lam, C.; Cobham, M.V.; Donovan, D.; Scheff, R.J.; Cigler, T.; Moore, A.; Vahdat, L.T.; Lane, M.E.; Chuang, E. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer, 2015, 15, 267.
[58]
Gómez Peña, C.; Dávila-Fajardo, C.L.; Martínez-González, L.J.; Carmona-Sáez, P.; Soto Pino, M.J.; Sánchez Ramos, J.; Moreno Escobar, E.; Blancas, I.; Fernández, J.J.; Fernández, D.; Correa, C.; Cabeza Barrera, J. Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis. Pharmacogenet. Genomics, 2015, 25, 388-393.
[59]
Baselga, J.; Swain, S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer, 2009, 9, 463-475.

Rights & Permissions Print Cite
Article Metrics
162
15
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy